<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39436878</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Ethical acceptability of human challenge trials: Consultation with the US public and with research personnel.</ArticleTitle><Pagination><StartPage>e0307808</StartPage><MedlinePgn>e0307808</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0307808</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0307808</ELocationID><Abstract><AbstractText>Human challenge trials (HCTs) may accelerate the development of treatments and vaccines, and deliver novel insights into the course and consequences of infection. However, HCTs are contentious because they involve purposely exposing volunteers to infection. Consultation with the public and other stakeholders is essential for understanding how HCTs can be most ethically and acceptably pursued. Previous research has found public support for COVID-19 HCTs, but little research has considered public attitudes towards HCTs in principle and the various factors making a trial more or less acceptable. Empirical data on the attitudes of research personnel is also missing. We generated an online survey covering overarching support/opposition towards HCTs, as well as factors of importance for deciding whether or not an HCT is ethically acceptable. Our sample of the US public represents the responses of 1500 participants sampled via Prolific, poststratified to be representative of the general US adult population. We additionally collected a convenience sample of 33 research personnel engaged in phase III clinical trials for infectious diseases. Estimates for the US public suggest substantial support for using HCTs to develop new vaccines, new treatments, and knowledge about diseases, with similarly high support among research personnel. The most important factors in determining acceptability of an HCT were the risk to participants and their comprehension of this risk. The general public, in particular, appear relatively unconcerned about participants' motivations, and favor higher payment in accordance with risk. This study adds to a growing body of public consultation surrounding HCTs, demonstrating high levels of support for their use in principle-not just in relation to COVID-19. The importance attributed to various ethically-relevant factors can help in designing HCTs with high public acceptance.</AbstractText><CopyrightInformation>Copyright: © 2024 Elsey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elsey</LastName><ForeName>James William Benjamin</ForeName><Initials>JWB</Initials><Identifier Source="ORCID">0009-0004-3292-7510</Identifier><AffiliationInfo><Affiliation>Rethink Priorities, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manheim</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8599-8380</Identifier><AffiliationInfo><Affiliation>Technion, Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5635-181X</Identifier><AffiliationInfo><Affiliation>Department of Psychology, Georgetown University, Washington, DC, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmit</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1Day Sooner Research Team, Delaware, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0795-8687</Identifier><AffiliationInfo><Affiliation>Rethink Priorities, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012108" MajorTopicYN="Y">Research Personnel</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011639" MajorTopicYN="N">Public Opinion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>This work was supported by an ACX Grant to 1Day Sooner, a 501(c)(3) non-profit organization that advocates for people who participate and want to participate in high-impact medical studies, including HCTs. Rethink Priorities was contracted by 1Day Sooner to execute this research project and collected and analyzed data independently of 1Day Sooner. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436878</ArticleId><ArticleId IdType="pmc">PMC11495607</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0307808</ArticleId><ArticleId IdType="pii">PONE-D-23-31643</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roser M, Ritchie H, Spooner F. Our World In Data.
2021.  [cited 2023 Jul 18]. Burden of disease. Available from: https://ourworldindata.org/burden-of-disease
doi: 10.3390/data6060063</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/data6060063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirleaf EJ, Clark H. Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic. The Lancet. 2021;398(10295):101–3. doi: 10.1016/S0140-6736(21)01095-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01095-3</ArticleId><ArticleId IdType="pmc">PMC9751704</ArticleId><ArticleId IdType="pubmed">33991477</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis. 2020;221(11):1752–6. doi: 10.1093/infdis/jiaa152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa152</ArticleId><ArticleId IdType="pmc">PMC7184325</ArticleId><ArticleId IdType="pubmed">32232474</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamrozik E, Littler K, Bull S, Emerson C, Kang G, Kapulu M, et al.. Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. Vaccine. 2021;39(4):633–40. doi: 10.1016/j.vaccine.2020.10.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.10.075</ArticleId><ArticleId IdType="pmc">PMC7598752</ArticleId><ArticleId IdType="pubmed">33341309</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. Lancet Infect Dis. 2020;20(8):e198–203. doi: 10.1016/S1473-3099(20)30438-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30438-2</ArticleId><ArticleId IdType="pmc">PMC7259898</ArticleId><ArticleId IdType="pubmed">32479747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer GO, Tam CC, Savulescu J, Voo TC. COVID-19 vaccine development: time to consider SARS-CoV-2 challenge studies? Vaccine. 2020;38(33):5085–8. doi: 10.1016/j.vaccine.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7269942</ArticleId><ArticleId IdType="pubmed">32540271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekhar A, Kang G. Human challenge trials in vaccine development. In: Seminars in Immunology. Elsevier; 2020. p. 101429. doi: 10.1016/j.smim.2020.101429</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2020.101429</ArticleId><ArticleId IdType="pmc">PMC7700100</ArticleId><ArticleId IdType="pubmed">33262068</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams-Phipps J, Toomey D, Więcek W, Schmit V, Wilkinson J, Scholl K, et al.. A systematic review of human challenge trials, designs, and safety. Clin Infect Dis. 2023;76(4):609–19. doi: 10.1093/cid/ciac820</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac820</ArticleId><ArticleId IdType="pmc">PMC9938741</ArticleId><ArticleId IdType="pubmed">36219704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. The Truest Test. American Association for the Advancement of Science; 2016. doi: 10.1126/science.352.6288.882</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.352.6288.882</ArticleId><ArticleId IdType="pubmed">27199398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby T. COVID-19 human challenge studies in the UK. Lancet Respir Med. 2020;8(12):e96. doi: 10.1016/S2213-2600(20)30518-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30518-X</ArticleId><ArticleId IdType="pmc">PMC7831781</ArticleId><ArticleId IdType="pubmed">33137284</ArticleId></ArticleIdList></Reference><Reference><Citation>Government UK. World’s first coronavirus Human Challenge study receives ethics approval in the UK [Internet]. 2021. 
Feb. Available from: https://www.gov.uk/government/news/worlds-first-coronavirus-human-challenge-study-receives-ethics-approval-in-the-uk</Citation></Reference><Reference><Citation>Rapeport G, Smith E, Gilbert A, Catchpole A, McShane H, Chiu C. SARS-CoV-2 human challenge studies—establishing the model during an evolving pandemic. N Engl J Med. 2021;385(11):961–4. doi: 10.1056/NEJMp2106970</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2106970</ArticleId><ArticleId IdType="pubmed">34289273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LC, Bakerlee CW, McKelvey TG, Rose SM, Norman AJ, Joseph N, et al.. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development. Clin Infect Dis. 2021;72(4):710–5. doi: 10.1093/cid/ciaa935</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa935</ArticleId><ArticleId IdType="pmc">PMC7454474</ArticleId><ArticleId IdType="pubmed">32628748</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson L, Earl J, Livezey J. Severe acute respiratory syndrome coronavirus 2 human challenge trials: too risky, too soon. J Infect Dis. 2020;222(3):514–6. doi: 10.1093/infdis/jiaa314</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa314</ArticleId><ArticleId IdType="pmc">PMC7313940</ArticleId><ArticleId IdType="pubmed">32496536</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers DL, Fowler CB, Mason JT, Mimnall RK. Deliberate microbial infection research reveals limitations to current safety protections of healthy human subjects. Sci Eng Ethics. 2015;21:1049–64. doi: 10.1007/s11948-014-9579-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11948-014-9579-z</ArticleId><ArticleId IdType="pubmed">25150847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbesemete D, Barker M, Lawrence WT, Watson D, De Graaf H, Read RC. Exploring the acceptability of controlled human infection with SARSCoV2—a public consultation. BMC Med. 2020;18(1):1–8. doi: 10.1186/s12916-019-1443-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1443-1</ArticleId><ArticleId IdType="pmc">PMC7339437</ArticleId><ArticleId IdType="pubmed">32635912</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh AA, Magalhaes M, Peeler M, Rose SM, Darton TC, Eyal N, et al.. Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials. Plos One. 2022;17(11):e0275823. doi: 10.1371/journal.pone.0275823</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0275823</ArticleId><ArticleId IdType="pmc">PMC9629635</ArticleId><ArticleId IdType="pubmed">36322529</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker C, Collet K, Gbesemete D, Piggin M, Watson D, Pristerà P, et al.. Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study. Wellcome Open Res. 2022;7. doi: 10.12688/wellcomeopenres.17516.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.17516.1</ArticleId><ArticleId IdType="pmc">PMC8921687</ArticleId><ArticleId IdType="pubmed">35321005</ArticleId></ArticleIdList></Reference><Reference><Citation>Broockman D, Kalla J, Guerrero A, Budolfson M, Eyal N, Jewell NP, et al.. Broad cross-national public support for accelerated COVID-19 vaccine trial designs. Vaccine. 2021. Jan;39(2):309–16. doi: 10.1016/j.vaccine.2020.11.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.11.072</ArticleId><ArticleId IdType="pmc">PMC7831807</ArticleId><ArticleId IdType="pubmed">33334616</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Census Bureau. Why we ask questions about sex [Internet]. 2019.  [cited 2023 Jun 7]. Available from: https://www.census.gov/acs/www/about/why-we-ask-each-question/sex/</Citation></Reference><Reference><Citation>Park DK, Gelman A, Bafumi J. Bayesian multilevel estimation with poststratification: State-level estimates from national polls. Polit Anal. 2004;12(4):375–85.</Citation></Reference><Reference><Citation>Downes M, Gurrin LC, English DR, Pirkis J, Currier D, Spittal MJ, et al.. Multilevel regression and poststratification: a modeling approach to estimating population quantities from highly selected survey samples. Am J Epidemiol. 2018;187(8):1780–90. doi: 10.1093/aje/kwy070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy070</ArticleId><ArticleId IdType="pubmed">29635276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy L, Gelman A. Know your population and know your model: Using model-based regression and poststratification to generalize findings beyond the observed sample. Psychol Methods. 2021;26(5):547. doi: 10.1037/met0000362</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/met0000362</ArticleId><ArticleId IdType="pmc">PMC9187362</ArticleId><ArticleId IdType="pubmed">33793269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Rothschild D, Goel S, Gelman A. Forecasting elections with non-representative polls. Int J Forecast. 2015;31(3):980–91.</Citation></Reference><Reference><Citation>Morning Consult. COVID-19 Vaccine Dashboard [Internet]. 2022.  [cited 2022 Oct 2]. Available from: https://morningconsult.com/COVID19-vaccine-dashboard/</Citation></Reference><Reference><Citation>U.S. Census Bureau. American Community Survey 5-year Public Use Microdata Samples. 2021.</Citation></Reference><Reference><Citation>Schaffner B, Ansolabehere S, Luks S. Cooperative Election Study Common Content, 2020 [Internet]. Harvard Dataverse;
2021.  [cited 2023 Jul 6]. Available from: https://dataverse.harvard.edu/citation?persistentId=doi:10.7910/DVN/E9N6PH</Citation><ArticleIdList><ArticleId IdType="doi">10.7910/DVN/E9N6PH</ArticleId></ArticleIdList></Reference><Reference><Citation>FiveThirtyEight.
Biden Approval Rating [Internet]. 2022. Available from: https://projects.fivethirtyeight.com/biden-approval-rating/</Citation></Reference><Reference><Citation>Ruscio J. A probability-based measure of effect size: robustness to base rates and other factors. Psychol Methods. 2008;13(1):19. doi: 10.1037/1082-989X.13.1.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.13.1.19</ArticleId><ArticleId IdType="pubmed">18331151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruschke JK. Rejecting or accepting parameter values in Bayesian estimation. Adv Methods Pract Psychol Sci. 2018;1(2):270–80.</Citation></Reference><Reference><Citation>Grice JW. Observation oriented modeling: Analysis of cause in the behavioral sciences. Academic Press; 2011.</Citation></Reference><Reference><Citation>Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics. 2016;9(1):92–103. doi: 10.1093/phe/phv026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/phe/phv026</ArticleId><ArticleId IdType="pmc">PMC5926904</ArticleId><ArticleId IdType="pubmed">29731811</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberts JD, Zimmer-Harwood P, Elsey JW, Fraser-Urquhart A, Smiley T. Volunteering for infection: participant perspectives on a hepatitis C virus controlled human infection model. Clin Infect Dis. 2023;77(Supplement_3):S224–30. doi: 10.1093/cid/ciad350</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad350</ArticleId><ArticleId IdType="pmc">PMC10425139</ArticleId><ArticleId IdType="pubmed">37579204</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimwade O, Savulescu J, Giubilini A, Oakley J, Osowicki J, Pollard AJ, et al.. Payment in challenge studies: ethics, attitudes and a new payment for risk model. J Med Ethics. 2020;46(12):815–26. doi: 10.1136/medethics-2020-106438</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/medethics-2020-106438</ArticleId><ArticleId IdType="pmc">PMC7719900</ArticleId><ArticleId IdType="pubmed">32978306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzer J. Scandals have eroded US public’s confidence in drug industry. British Medical Journal Publishing Group; 2004. doi: 10.1136/bmj.329.7460.247</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.329.7460.247</ArticleId><ArticleId IdType="pmc">PMC498013</ArticleId><ArticleId IdType="pubmed">15284128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>